Elucida Oncology, Inc.
Elucida Oncology, Inc. is a breakthrough innovation company developing a new generation of cancer diagnostics and therapeutics. Their first product, C-Dots, is in early human clinical trials, enabling surgeons to see cancer in real-time during surgery. The company has a strong pipeline of therapeutic applications progressing through preclinical development. Starting with melanoma and breast cancer, Elucida Oncology is bringing new solutions into the world of true precision medicine.
The Company IP is licensed from Cornell University and Memorial Sloan Kettering Cancer Center. C-Dots were envisioned and invented by a professor in the Department of Materials Science and Engineering at Cornell. Clinical translation was achieved in partnership with the leadership of a doctor at MSKCC. Both are company cofounders.